Edward B. Garon, MD, on NSCLC: Long-Term Use of Pemetrexed Plus Platinum With Pembrolizumab

May 13, 2020 By The ASCO Post Staff

Edward B. Garon, MD, of the University of California, Los Angeles David Geffen School of Medicine, discusses KEYNOTE-189 trial findings that showed adding pembrolizumab to pemetrexed plus platinum—which previously was found to improve overall and progression-free survival—is also safe and has manageable toxicity in long-term use for patients with metastatic nonsquamous non–small cell lung cancer (Abstract CT085).

Related Content